NCT00449527

Brief Summary

The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) using a 1 week recall period versus a 1 day recall period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
123

participants targeted

Target at P25-P50 for phase_3 asthma

Timeline
Completed

Started Mar 2007

Shorter than P25 for phase_3 asthma

Geographic Reach
1 country

44 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2007

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

March 16, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 20, 2007

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2007

Completed
Last Updated

January 24, 2011

Status Verified

January 1, 2011

First QC Date

March 16, 2007

Last Update Submit

January 21, 2011

Conditions

Keywords

Mild asthmaModerate asthma

Outcome Measures

Primary Outcomes (1)

  • To demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) items 2 and 5 using a 1 week recall period versus a 1 day recall period.

Secondary Outcomes (1)

  • To demonstrate the value to subjects of feeling an asthma maintenance medication begins to work right away; to assess the correlation between subject's responses to weekly/daily Onset of Effect Questionnaires with lung function and with diary variables.

Interventions

Also known as: Symbicort

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or Female, \> 18 years of age
  • Mild to moderate asthma requiring treatment with an inhaled corticosteroid
  • Diagnosis of asthma for at least 6 months

You may not qualify if:

  • Subjects requiring treatment with systemic corticosteroids (e.g., oral, parenteral, ocular)
  • Subjects with severe asthma, as judged by investigator
  • Any significant disease or disorder that may jeopardize a subject's safety

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (44)

Research Site

Tuscumbia, Alabama, United States

Location

Research Site

Fort Smith, Arkansas, United States

Location

Research Site

Long Beach, California, United States

Location

Research Site

Orange, California, United States

Location

Research Site

Riverside, California, United States

Location

Research Site

Sacramento, California, United States

Location

Research Site

San Diego, California, United States

Location

Research Site

San Jose, California, United States

Location

Research Site

Colorado Springs, Colorado, United States

Location

Research Site

Denver, Colorado, United States

Location

Research Site

Valrico, Florida, United States

Location

Research Site

River Forest, Illinois, United States

Location

Research Site

Council Bluffs, Iowa, United States

Location

Research Site

Topeka, Kansas, United States

Location

Research Site

Wichita, Kansas, United States

Location

Research Site

Bowling Green, Kentucky, United States

Location

Research Site

Florence, Kentucky, United States

Location

Research Site

Metairie, Louisiana, United States

Location

Research Site

City of Saint Peters, Missouri, United States

Location

Research Site

St Louis, Missouri, United States

Location

Research Site

Butte, Montana, United States

Location

Research Site

Omaha, Nebraska, United States

Location

Research Site

Papillion, Nebraska, United States

Location

Research Site

Las Vegas, Nevada, United States

Location

Research Site

Skillman, New Jersey, United States

Location

Research Site

Summit, New Jersey, United States

Location

Research Site

Albuquerque, New Mexico, United States

Location

Research Site

New York, New York, United States

Location

Research Site

North Syracuse, New York, United States

Location

Research Site

Rochester, New York, United States

Location

Research Site

Greensboro, North Carolina, United States

Location

Research Site

Mooresville, North Carolina, United States

Location

Research Site

Oklahoma City, Oklahoma, United States

Location

Research Site

Tulsa, Oklahoma, United States

Location

Research Site

Collegeville, Pennsylvania, United States

Location

Research Site

Charleston, South Carolina, United States

Location

Research Site

Greenville, South Carolina, United States

Location

Research Site

Spartanburg, South Carolina, United States

Location

Research Site

Union, South Carolina, United States

Location

Research Site

Dallas, Texas, United States

Location

Research Site

South Burlington, Vermont, United States

Location

Research Site

Bellingham, Washington, United States

Location

Research Site

Spokane, Washington, United States

Location

Research Site

Tacoma, Washington, United States

Location

Related Publications (1)

  • Leidy NK, Gutierrez B, Lampl K, Uryniak T, O'Brien CD. Can patients with asthma feel inhaler therapy working right away? Two clinical trials testing the effect of timing of assessment on patient perception. J Asthma. 2009 Dec;46(10):1006-12. doi: 10.3109/02770900903301260.

Related Links

MeSH Terms

Conditions

Asthma

Interventions

BudesonideBudesonide, Formoterol Fumarate Drug Combination

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

PregnenedionesPregnenesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsFormoterol FumarateEthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesDrug CombinationsPharmaceutical Preparations

Study Officials

  • Tomas LG Andersson, MD

    AstraZeneca

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

March 16, 2007

First Posted

March 20, 2007

Study Start

March 1, 2007

Study Completion

August 1, 2007

Last Updated

January 24, 2011

Record last verified: 2011-01

Locations